Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

21.31 USD -0.02 (-0.09%)
Official Closing Price Updated: 7:48 PM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,579,563
Open 21.25
Bid (Size) 20.50 (10)
Ask (Size) 21.20 (1)
Prev. Close 21.33
Today's Range 20.86 - 21.65
52wk Range 13.67 - 27.80
Shares Outstanding 296,866,380
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European... 
From Business Wire News Releases
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in fireside chats at the following virtual investor... 
From Business Wire News Releases

Performance

YTD
+3.80%
+3.80%
1 Month
-5.54%
-5.54%
3 Month
+13.11%
+13.11%
6 Month
+2.80%
+2.80%
1 Year
+7.14%
+7.14%

More News

Read More
Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Business Wire News Releases
Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021
From Business Wire News Releases
European Medicines Agency's CHMP Backs Approval Of Cabometyx/Opdivo Combo In Kidney Cancer
Tags Kidney Cancer EXEL News
From Benzinga
Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU
From Business Wire News Releases
Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients
From Business Wire News Releases
Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer
Tags Market News Thyroid Cancer Benzinga
From Benzinga
Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
From Business Wire News Releases
Analysts Expect PBE Will Reach $85
Tags ETFs
From ETF Channel
Exelixis Breaks Above 200-Day Moving Average - Bullish for EXEL
Tags Stocks
From Market News Video
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.